New treatment strategies for Hodgkin's lymphoma

Leukemia Research

Volumn 33, Issue 7, 2009, Pages 886-888

  Staege, Martin Sebastian ^a   Körholz, Dieter ^b  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLAVOPIRIDOL; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; ROMIDEPSIN;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CARCINOGENESIS; DRUG MECHANISM; EDITORIAL; EPIGENETICS; HODGKIN DISEASE; HUMAN; LYMPHOMA CELL; PATHOGENESIS; PRIORITY JOURNAL;

ANTIBIOTICS, ANTINEOPLASTIC; DEPSIPEPTIDES; HISTONE DEACETYLASES; HODGKIN DISEASE; HUMANS;

EID: 67349171559     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.01.021     Document Type: Editorial

References (62)

1. Körholz D., Claviez A., Hasenclever D., Kluge R., Hirsch W., Kamprad F., et al. The concept of the GPOH-HD 2003 therapy study for pediatric Hodgkin's disease: evolution in the tradition of the DAL/GPOH studies. Klin Padiatr 216 (2004) 150-156
2. Travis L.B., Hill D., Dores G.M., Gospodarowicz M., van Leeuwen F.E., Holowaty E., et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 97 (2005) 1428-1437
3. Brusa G., Zuffa E., Hattinger C.M., Serra M., Remondini D., Castellani G., et al. Genomic imbalances associated with secondary acute leukemias in Hodgkin lymphoma. Oncol Rep 18 (2007) 1427-1434
4. Boukheris H., Ron E., Dores G.M., Stovall M., Smith S.A., and Curtis R.E. Risk of radiation-related salivary gland carcinomas among survivors of Hodgkin lymphoma: a population-based analysis. Cancer 113 (2008) 3153-3159
5. Aleman B.M., van den Belt-Dusebout A.W., De Bruin M.L., van 't Veer M.B., Baaijens M.H., de Boer J.P., et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 109 (2007) 1878-1886
6. Boice Jr. J.D. An affair of the heart. J Natl Cancer Inst 99 (2007) 186-187
7. Swerdlow A.J., Higgins C.D., Smith P., Cunningham D., Hancock B.W., Horwich A., et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst 99 (2007) 206-214
8. van der Kaaij M.A., Heutte N., Le Stang N., Raemaekers J.M., Simons A.H., Carde P., et al. Gonadal function in males after chemotherapy for early-stage Hodgkin's lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 25 (2007) 2825-2832
9. Sieniawski M., Reineke T., Josting A., Nogova L., Behringer K., Halbsguth T., et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Ann Oncol 19 (2008) 1795-1801
10. Drexler H.G., and Minowada J. Hodgkin's disease derived cell lines: a review. Hum Cell 5 (1992) 42-53
11. Schwering I., Bräuninger A., Klein U., Jungnickel B., Tinguely M., Diehl V., et al. Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 101 (2003) 1505-1512
12. Weniger M.A., Barth T.F., and Möller P. Genomic alterations in Hodgkin's lymphoma. Int J Hematol 83 (2006) 379-384
13. Hartmann S., Martin-Subero J.I., Gesk S., Hüsken J., Giefing M., Nagel I., et al. Detection of genomic imbalances in microdissected Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma by array-based comparative genomic hybridization. Haematologica 93 (2008) 1318-1326
14. Falzetti D., Crescenzi B., Matteuci C., Falini B., Martelli M.F., Van Den Berghe H., et al. Genomic instability and recurrent breakpoints are main cytogenetic findings in Hodgkin's disease. Haematologica 84 (1999) 298-305
15. Doerr J.R., Malone C.S., Fike F.M., Gordon M.S., Soghomonian S.V., Thomas R.K., et al. Patterned CpG methylation of silenced B cell gene promoters in classical Hodgkin lymphoma-derived and primary effusion lymphoma cell lines. J Mol Biol 350 (2005) 631-640
16. Ying J., Li H., Murray P., Gao Z., Chen Y.W., Wang Y., et al. Tumor-specific methylation of the 8p22 tumor suppressor gene DLC1 is an epigenetic biomarker for Hodgkin, nasal NK/T-cell and other types of lymphomas. Epigenetics 2 (2007) 15-21
17. Ying J., Gao Z., Li H., Srivastava G., Murray P.G., Goh H.K., et al. Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies. Br J Haematol 136 (2007) 829-832
18. Ehlers A., Oker E., Bentink S., Lenze D., Stein H., and Hummel M. Histone acetylation and DNA demethylation of B cells result in a Hodgkin-like phenotype. Leukemia 22 (2008) 835-841
19. Akimzhanov A., Krenacs L., Schlegel T., Klein-Hessling S., Bagdi E., Stelkovics E., et al. Epigenetic changes and suppression of the nuclear factor of activated T cell 1 (NFATC1) promoter in human lymphomas with defects in immunoreceptor signaling. Am J Pathol 172 (2008) 215-224
20. Bolden J.E., Peart M.J., and Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5 (2006) 769-784
21. Carew J.S., Giles F.J., and Nawrocki S.T. Histon deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 269 (2008) 7-17
22. Lee M.J., Kim Y.S., Kummar S., Giaccone G., and Trepel J.B. Histone deacetylase inhibitors in cancer therapy. Curr Opin Oncol 20 (2008) 639-649
23. Hartlapp I., Pallasch C., Weibert G., Kemkers A., Hummel M., and Re D. Depstipeptide induces cell death in Hodgkin lymphoma-derived cell lines. Leukemia Res 33 (2009) 929-936
24. Konstantinopoulos P.A., Vandoros G.P., and Papavassiliou A.G. FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities. Cancer Chemother Pharmacol 58 (2006) 711-715
25. Hoshino I., Matsubara H., Hanari N., Mori M., Nishimori T., Yoneyama Y., et al. Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells. Clin Cancer Res 11 (2005) 7945-7952
26. Sakimura R., Tanaka K., Nakatani F., Matsunobu T., Li X., Hanada M., et al. Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors. Int J Cancer 116 (2005) 784-792
27. Berg T., Fliegauf M., Burger J., Staege M.S., Liu S., Martinez N., et al. Transcriptional upregulation of p21/WAF/Cip1 in myeloid leukemic blasts expressing AML1-ETO. Haematologica 93 (2008) 1728-1733
28. Nakatani F., Tanaka K., Sakimura R., Matsumoto Y., Matsunobu T., Li X., et al. Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein. J Biol Chem 278 (2003) 15105-15115
29. Galmarini C.M., Bouchet B.P., Audoynaud C., Lamblot C., Falette N., Bertholon J., et al. A p21/WAF1 mutation favors the appearance of drug resistance to paclitaxel in human noncancerous epithelial mammary cells. Int J Cancer 119 (2006) 60-66
30. Mousses S., Ozçelik H., Lee P.D., Malkin D., Bull S.B., and Andrulis I.L. Two variants of the CIP1/WAF1 gene occur together and are associated with human cancer. Hum Mol Genet 4 (1995) 1089-1092
31. Staalesen V., Knappskog S., Chrisanthar R., Nordgard S.H., Løkkevik E., Anker G., et al. The novel p21 polymorphism p21G251A is associated with locally advanced breast cancer. Clin Cancer Res 12 (2006) 6000-6004
32. Mitani Y., Oue N., Hamai Y., Aung P.P., Matsumura S., Nakayama H., et al. Histone H3 acetylation is associated with reduced p21(WAF1/CIP1) expression by gastric carcinoma. J Pathol 205 (2005) 65-73
33. Chen Y.X., Fang J.Y., Lu R., and Qiu D.K. Expression of p21(WAF1) is related to acetylation of histone H3 in total chromatin in human colorectal cancer. World J Gastroenterol 13 (2007) 2209-2213
34. Fang J.Y., and Lu Y.Y. Effects of histone acetylation and DNA methylation on p21(WAF1) regulation. World J Gastroenterol 8 (2002) 400-405
35. Hellebrekers D.M., Melotte V., Viré E., Langenkamp E., Molema G., Fuks F., et al. Identification of epigenetically silenced genes in tumor endothelial cells. Cancer Res 67 (2007) 4138-4148
36. Magnaghi-Jaulin L., Eot-Houllier G., Fulcrand G., and Jaulin C. Histone deacetylase inhibitors induce premature sister chromatid separation and override the mitotic spindle assembly checkpoint. Cancer Res 67 (2007) 6360-6367
37. Witt O., Deubzer H.E., Milde T., and Oehme I. HDAC family: What are the cancer relevant targets?. Cancer Lett Sep (2008) [Epub ahead of print]
38. Ocio E.M., Mateos M.V., Maiso P., Pandiella A., and San-Miguel J.F. New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncol 9 (2008) 1157-1165
39. Oflazoglu E., Kissler K.M., Sievers E.L., Grewal I.S., and Gerber H.P. Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. Br J Haematol 14 (2008) 69-73
40. Cerveny C.G., Law C.L., McCormick R.S., Lenox J.S., Hamblett K.J., Westendorf L.E., et al. Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics. Leukemia 19 (2005) 1648-1655
41. Hou J., Wang D., Zhang R., and Wang H. Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action. Clin Cancer Res 14 (2008) 5519-5530
42. Bu Y., Lu C., Bian C., Wang J., Li J., Zhang B., et al. Knockdown of Dicer in MCF-7 human breast carcinoma cells results in G1 arrest and increased sensitivity to cisplatin. Oncol Rep 21 (2009) 13-17
43. Nguyen D.M., Schrump W.D., Chen G.A., Tsai W., Nguyen P., Trepel J.B., et al. Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells. Clin Cancer Res 10 (2004) 1813-1825
44. Lazzarini R., Moretti S., Orecchia S., Betta P.G., Procopio A., and Catalano A. Enhanced antitumor therapy by inhibition of p21waf1 in human malignant mesothelioma. Clin Cancer Res 14 (2008) 5099-5107
45. Foell J., Hewes B., and Mittler R.S. T cell costimulatory and inhibitory receptors as therapeutic targets for inducing anti-tumor immunity. Curr Cancer Drug Targets 7 (2007) 55-70
46. Lynch D.H. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer. Immunol Rev 222 (2008) 277-286
47. Sánchez-Aguilera A., Montalbán C., de la Cueva P., Sánchez-Verde L., Morente M.M., García-Cosío M., et al. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood 108 (2006) 662-668
48. Marshall N.A., Christie L.E., Munro L.R., Culligan D.J., Johnston P.W., Barker R.N., et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 103 (2004) 1755-1762
49. Alvaro-Naranjo T., Lejeune M., Salvadó-Usach M.T., Bosch-Príncep R., Reverter-Branchat G., Jaén-Martínez J., et al. Tumor-infiltrating cells as a prognostic factor in Hodgkin's lymphoma: a quantitative tissue microarray study in a large retrospective cohort of 267 patients. Leuk Lymphoma 46 (2005) 1581-1591
50. Smith C., Cooper L., Burgess M., Rist M., Webb N., Lambley E., et al. Functional reversion of antigen-specific CD8+ T cells from patients with Hodgkin lymphoma following in vitro stimulation with recombinant polyepitope. J Immunol 177 (2006) 4897-4906
51. Diepstra A., van Imhoff G.W., Karim-Kos H.E., van den Berg A., te Meerman G.J., Niens M., et al. HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma. J Clin Oncol 25 (2007) 3101-3108
52. Buglio D., Georgakis G.V., Hanabuchi S., Arima K., Khaskhely N.M., Liu Y.J., et al. Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood 112 (2008) 1424-1433
53. Bollard C.M., Aguilar L., Straathof K.C., Gahn B., Huls M.H., Rousseau A., et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med 200 (2004) 1623-1633
54. Peggs K.S., Hunter A., Chopra R., Parker A., Mahendra P., Milligan D., et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 365 (2005) 1934-1941
55. Staege M.S., Banning-Eichenseer U., Weissflog G., Volkmer I., Burdach S., Richter G., et al. Gene expression profiles of Hodgkin's lymphoma cell lines with different sensitivity to cytotoxic drugs. Exp Hematol 36 (2008) 886-896
56. Griffioen M., Kessler J.H., Borghi M., van Soest R.A., van der Minne C.E., Nouta J., et al. Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy. Clin Cancer Res 12 (2006) 3130-3136
57. Morandi F., Chiesa S., Bocca P., Millo E., Salis A., Solari M., et al. Tumor mRNA-transfected dendritic cells stimulate the generation of CTL that recognize neuroblastoma-associated antigens and kill tumor cells: immunotherapeutic implications. Neoplasia 8 (2006) 833-842
58. Quintarelli C., Dotti G., De Angelis B., Hoyos V., Mims M., Luciano L., et al. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. Blood 112 (2008) 1876-1885
59. Li B., and Greene M.I. FOXP3 actively represses transcription by recruiting the HAT/HDAC complex. Cell Cycle 6 (2007) 1432-1436
60. Villagra A., Cheng F., Wang H.W., Suarez I., Glozak M., Maurin M., et al. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol 10 (2009) 92-100
61. Bosisio D., Vulcano M., Del Prete A., Sironi M., Salvi V., Salogni L., et al. Blocking TH17-polarizing cytokines by histone deacetylase inhibitors in vitro and in vivo. J Leukoc Biol 84 (2008) 1540-1548
62. Reddy P., Sun Y., Toubai T., Duran-Struuck R., Clouthier S.G., Weisiger E., et al. Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J Clin Invest 118 (2008) 2562-2573